8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 14, 2007

Integrated BioPharma, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

000-28876	22-2407475
(Commission File Number)	(IRS Employer Identification No.)

225 Long Avenue, Hillside, New Jersey	07205
(Address of Principal Executive Offices)	(Zip Code)

(973) 926-0816

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On November 14, 2007, Integrated BioPharma, Inc. issued a press release announcing results for its quarter ended September 30, 2007. The press release is attached as an exhibit to this Report.

The information in this Item 2.02, and in Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof, regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered "filed" or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits

(c) Exhibits.

 

Exhibit No.	Description
99.1	Press Release issued by Integrated BioPharma, Inc. on November 14, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

	INTEGRATED BIOPHARMA, INC.
Date: November 14, 2007	By: /s/ Dina Masi
	Dina Masi
	Chief Financial Officer

EX-99

Exhibit 99.1
 

 

NEWS RELEASE for November 14, 2007

Contact: Dina Masi, CFO
Jeffrey Leach, Investor Relations
Integrated BioPharma, Inc.
j.leach@ibiopharma.com
888.319.6962

Integrated BioPharma Reports Results for its Quarter Ended September 30, 2007

Hillside, N.J., November 14, 2007—Integrated BioPharma, Inc. (NasdaqGM:INBP) reported financial results today for its first quarter ended September 30, 2007. Revenues for the quarter ended September 30, 2007 were $12.6 million compared to $12.9 million for the quarter ended September 30, 2006. Operating income for the quarter ended September 30, 2007 was a loss of $1.5 million compared to operating income of $368,000 for the quarter ended September 30, 2006. The Company’s increase of $1.8 million in operating losses is primarily attributable to the acquisition it made in its fiscal 2007 third quarter in its Nutraceutical Segment, which resulted in increased selling and administrative costs, including marketing costs, with no significant sales in the current quarter, increased consulting professional fees in its Biotechnologies Segment and an increase in our cost of goods sold in our Pharmaceuticals Segment resulting from increased sales in this segment. As previously announced, the Company expects to spin off its biotech business to the Company’s shareholders, after which the biotech business will be separately financed and will operate as a wholly-separate company.
 
For the quarter ended September 30, 2007, there was a net loss applicable to common shareholders of $1.3 million or ($0.09), compared with a net loss applicable to common shareholders of $514,000, or ($0.04) per diluted share, for the quarter ended September 30, 2006. Net loss applicable to common shareholders is calculated after cash Preferred Stock dividends of $119,000 and non-cash Preferred Stock deemed dividends of $563,000 for the quarter ended September 30, 2006.
 
A summary of our financial results for the quarter ended September 30, 2007 and 2006 is presented below:

About Integrated BioPharma, Inc. (INBP)

Integrated BioPharma, Inc. is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company’s biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.iBioPharma.com.

Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.